Compass Pathways (NASDAQ:CMPS) Rating Lowered to Strong Sell at Wall Street Zen

Compass Pathways (NASDAQ:CMPS) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

CMPS has been the topic of several other reports. Compass Point set a $25.00 price objective on shares of Compass Pathways in a report on Tuesday, July 7th. Wells Fargo & Company assumed coverage on shares of Compass Pathways in a research report on Monday, July 27th. They set an “equal weight” rating and a $13.00 target price for the company. BTIG Research upped their target price on shares of Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. B. Riley Financial boosted their price target on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Stifel Nicolaus lifted their price target on shares of Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.36.

Compass Pathways Stock Performance

NASDAQ:CMPS opened at $11.57 on Friday. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -2.50 and a beta of 2.43. The stock’s 50 day simple moving average is $12.91 and its two-hundred day simple moving average is $10.38. Compass Pathways has a 1 year low of $4.88 and a 1 year high of $15.87. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, equities analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Integrity Alliance LLC. acquired a new stake in shares of Compass Pathways in the 3rd quarter valued at about $128,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in Compass Pathways by 23.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 399,506 shares of the company’s stock valued at $4,970,000 after purchasing an additional 76,297 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Compass Pathways during the 3rd quarter worth $85,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Compass Pathways by 15.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,432 shares of the company’s stock worth $317,000 after buying an additional 3,249 shares in the last quarter. Finally, North Star Investment Management Corp. increased its stake in Compass Pathways by 23.9% during the 3rd quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock valued at $116,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.